Art Therapy in High-risk Obstetric Patients
Sponsor
Medstar Health Research Institute (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05503056
Collaborator
(none)
100
1
2
22.5
4.4
Study Details
Study Description
Brief Summary
This is a prospective study examining the potential impact art therapy has on postpartum depression and mother-baby bonding in women with high-risk pregnancies. Women who receive care at Washington Hospital Center's high-risk obstetrics clinic will be recruited for this study.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Supportive Care
Official Title:
The Impact of Art Therapy on Maternal Depression and Mother-infant Bonding in High-risk Pregnancies
Anticipated Study Start Date
:
Aug 15, 2022
Anticipated Primary Completion Date
:
Jun 30, 2023
Anticipated Study Completion Date
:
Jun 30, 2024
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Intervention Engage in six art therapy sessions |
Other: art therapy
six sessions of art therapy with licensed therapists
|
Placebo Comparator: Control Engage in usual activities |
Other: nothing
no intervention to this group
|
Outcome Measures
Primary Outcome Measures
- changes in Edinburgh Postnatal Depression Scale scores [start, middle, and end of intervention period, time of delivery, two weeks postpartum, six weeks postpartum, three months postpartum]
raw score on scale
- change in maternal-infant bonding scores [start, middle, and end of intervention period, time of delivery, two weeks postpartum, six weeks postpartum, three months postpartum]
raw score on scale
- utilization of behavioral health/psychology/psychiatry services during pregnancy and postpartum [12-16 months]
chart review to see if patients utilized services "yes" vs. "no"
- use of psychiatry medications during and after pregnancy [12-16 months]
chart review to see if patients utilized services "yes" vs. "no"
Secondary Outcome Measures
- obstetrical complications (postpartum hemorrhage, OASIS, ICU admission) [one month postpartum]
chart review
- gestational age at time of delivery [one month postpartum]
chart review
- mode of delivery [one month postpartum]
chart review
- reason for delivery (iatrogenic vs spontaneous) [one month postpartum]
chart review
- birth weight [one month postpartum]
chart review
- APGAR scores [one month postpartum]
chart review
- NICU admissions [one month postpartum]
chart review
- delivery complications (shoulder dystocia, low birth weight) [one month postpartum]
chart review
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- Participants will have to be eighteen years of age or older, in the second trimester of pregnancy at time of recruitment, speak and read English as their primary language, have access to a reliable internet/wifi connection to participate in therapy sessions, and plan to deliver at Washington Hospital Center
Exclusion Criteria:
- Women who do not meet those criteria will be excluded from recruitment
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Washington Hospital Center | Washington | District of Columbia | United States | 20010 |
Sponsors and Collaborators
- Medstar Health Research Institute
Investigators
- Principal Investigator: Sara N Iqbal, MD, Medstar
Study Documents (Full-Text)
None provided.More Information
Publications
Responsible Party:
Sara N. Iqbal,
Primary Investigator,
Medstar Health Research Institute
ClinicalTrials.gov Identifier:
NCT05503056
Other Study ID Numbers:
- 20223247
First Posted:
Aug 16, 2022
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: